AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 8 Best Healthcare AI Stocks to Buy According to Analysts. On April 22, 2026, JonesResearch highlighted AbCellera Biologics Inc. (NASDAQ:ABCL), noting that if its ABCL635 candidate demonstrates clean safety with no hepatic signals and achieves target engagement comparable to Veohah and Lynkuet, the therapy could be “very competitive.” The firm has reiterated its Buy rating and $11 price target on AbCellera Biologics Inc. (NASDAQ:ABCL) ahead of a Phase 1 ...

事件概述 - 罗森律师事务所宣布对ADMA Biologics Inc 可能存在的证券索赔进行调查 调查涉及该公司可能向投资公众发布了具有重大误导性的商业信息 [1] 事件起因 - 2026年3月24日 Investing com 发布文章称ADMA Biologics股价因做空机构指控而暴跌 做空机构Culper Research发布报告 指控该公司通过渠道填充来虚增收入增长 [3] - 受此消息影响 ADMA Biologics 股价在2026年3月24日当天下跌了16.6% [3] 法律行动进展 - 罗森律师事务所正在准备集体诉讼 旨在为投资者挽回损失 [2] - 符合条件的ADMA Biologics证券购买者可能有权通过风险代理收费安排获得赔偿 而无需支付任何自付费用或成本 [2]

NO INVESTMENT ADVICE The content on this Site is provided for information purposes only and does not constitute investment advice, a personal recommendation, an offer or solicitation to buy or sell securities, or any other regulated activity. It should not be relied upon as the basis for any investment decision. Before making any investment decision, you should: Read the relevant prospectus, term sheet, subscription agreement, or other offering documentation in full Consider whether the investment is suit ...